Catalog No.
DHE84601
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
GPC3, MXR7, GTR2-2, Glypican-3, Intestinal protein OCI-5, OCI5
Concentration
1.1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P51654
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
GC33, RG7686, RO5137382, CAS: 1365267-33-9
Clone ID
Codrituzumab
Note
For research use only. Not suitable for clinical or therapeutic use.
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma., PMID:27085251
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)., PMID:28120036
Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma., PMID:29381229
I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma., PMID:29508107
Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab., PMID:29535817
Case-control Indian buffet process identifies biomarkers of response to Codrituzumab., PMID:30922327
Glypican 3-Targeted Therapy in Hepatocellular Carcinoma., PMID:31510063
Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis., PMID:31528232
Heparan sulfate proteoglycans as targets for cancer therapy: a review., PMID:33180600
Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma., PMID:33374953
H2BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha Therapy., PMID:35670495
Glypican-3 deficiency in liver cancer upregulates MAPK/ERK pathway but decreases cell proliferation., PMID:39113871
Glypican-3 is a key tuner of the Hedgehog pathway in COPD., PMID:39844999
Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis, PMID: 31528232
Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma, PMID: 33374953
Heparan sulfate proteoglycans as targets for cancer therapy: a review, PMID: 33180600
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma, PMID: 27085251
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC), PMID: 28120036
Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab, PMID: 29535817
Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma, PMID: 29381229
Case-control Indian buffet process identifies biomarkers of response to Codrituzumab, PMID: 30922327
Glypican 3-Targeted Therapy in Hepatocellular Carcinoma, PMID: 31510063
I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma, PMID: 29508107
For research use only. Not for human or drug use.
